+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Liver And Kidney Disorders Drugs Market Research Reports

Angelman Syndrome- Pipeline Insight, 2025 - Product Thumbnail Image

Angelman Syndrome- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
End-Stage Renal Disease - Pipeline Insight, 2025 - Product Thumbnail Image

End-Stage Renal Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Hepatitis Delta Virus (HDV) Infection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
From
Alagille Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Alagille Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Chronic Hepatitis B Virus Infection - Pipeline Insight, 2025 - Product Thumbnail Image

Chronic Hepatitis B Virus Infection - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 200 Pages
  • Global
From
Minimal Change Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Minimal Change Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 40 Pages
  • Global
From
Moderate And Severe Chronic Kidney Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Moderate And Severe Chronic Kidney Disease - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Nephrotic Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Nephrotic Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
Advanced Renal Cell Carcinoma - Pipeline Insight, 2025 - Product Thumbnail Image

Advanced Renal Cell Carcinoma - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Hepatitis B Virus Infection - Pipeline Insight, 2025 - Product Thumbnail Image

Hepatitis B Virus Infection - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 180 Pages
  • Global
From
Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034 - Product Thumbnail Image

Complement 3 Glomerulopathy (C3G) - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 69 Pages
  • Global
From
From
Nephrotic Syndrome - Epidemiology Forecast - 2034 - Product Thumbnail Image

Nephrotic Syndrome - Epidemiology Forecast - 2034

  • Report
  • December 2024
  • 143 Pages
  • Global
From
From
From
From
Non-Alcoholic Steatohepatitis Market 2025-2033 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis Market 2025-2033

  • Report
  • March 2025
  • 142 Pages
  • Global
From
Renal Anemia Treatment - Global Strategic Business Report - Product Thumbnail Image

Renal Anemia Treatment - Global Strategic Business Report

  • Report
  • August 2025
  • 278 Pages
  • Global
From
Loading Indicator

The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share. The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market. Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more